{
  "extraction_metadata": {
    "timestamp": "2025-10-02T17:09:06.311131",
    "source_type": "clinical_guideline",
    "indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
    "total_countries": 12,
    "temperature": 0.1
  },
  "outcomes_by_country": {
    "AT": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "AT",
      "Outcomes": "response rate, progression-free survival, diarrhoea, dilation, nausea, transaminase increase, creatinine increase, QTc time prolongation, adverse reactions (general), serious adverse reactions (CTCAE grade 3/4)",
      "ChunksUsed": 7,
      "ContextTokens": 2924
    },
    "DE": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "DE",
      "Outcomes": "none stated",
      "ChunksUsed": 2,
      "ContextTokens": 705
    },
    "DK": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "DK",
      "Outcomes": "overall response rate, progression-free survival, overall survival, diarrhoea, alanine aminotransferase increase, aspartate aminotransferase increase, neutropenia, fatigue, febrile neutropenia, adverse events (grade 3 or higher)",
      "ChunksUsed": 8,
      "ContextTokens": 2663
    },
    "EL": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "EL",
      "Outcomes": "progression-free survival, overall survival",
      "ChunksUsed": 1,
      "ContextTokens": 331
    },
    "EN": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "EN",
      "Outcomes": "overall survival, progression-free survival, objective response rate (RECIST 1.1), complete response (RECIST 1.1), partial response (RECIST 1.1), health-related quality of life",
      "ChunksUsed": 12,
      "ContextTokens": 4737
    },
    "ES": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "ES",
      "Outcomes": "",
      "ChunksUsed": 1,
      "ContextTokens": 294
    },
    "EU": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "EU",
      "Outcomes": "",
      "ChunksUsed": 1,
      "ContextTokens": 463
    },
    "FR": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "FR",
      "Outcomes": "serious side effects on the skin",
      "ChunksUsed": 7,
      "ContextTokens": 2709
    },
    "IE": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "IE",
      "Outcomes": "",
      "ChunksUsed": 1,
      "ContextTokens": 305
    },
    "IT": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "IT",
      "Outcomes": "overall survival, progression free survivorship, overall response rate, disease progression at the interregional level, treatment discontinuation rate, adverse events, toxicity",
      "ChunksUsed": 2,
      "ContextTokens": 796
    },
    "NL": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "NL",
      "Outcomes": "progression free survival, overall survival, overall response rate, safety, patient reported outcomes, adverse events",
      "ChunksUsed": 5,
      "ContextTokens": 1955
    },
    "SE": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "SE",
      "Outcomes": "response rates, survival, progression-free survival, symptom control, preservation of quality of life",
      "ChunksUsed": 6,
      "ContextTokens": 1806
    }
  }
}